Skip to main content
SpringerLink
Log in

Empfehlungen zur antiretroviralen Therapie bei HIV-infizierten Kindern

Konsensus-Statement der Pädiatrischen Arbeitsgemeinschaft AIDS (PAAD) und der Deutschen Gesellschaft für Pädiatrische Infektiologie (DGPI)

  • Pädiatrie aktuell
  • Published:
Monatsschrift Kinderheilkunde Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Wahn V, Bialek R, Böhler T et al. (1998) Empfehlungen zur antiretroviralen Therapie bei HIV-infizierten Kindern. Monatsschr Kinderheilkd 146: 1081–1091

    Article  Google Scholar 

  2. Niehues T, Wintergerst U, Funk M, Notheis G für die Konsensusgruppe der Pädiatrischen Arbeitsgemeinschaft AIDS (PAAD) (2001) Empfehlungen zur antiretroviralen Therapie bei HIV-infizierten Kindern – Vollständig überarbeitetes und aktualisiertes Konsensus-Statement der Pädiatrischen Arbeitsgemeinschaft AIDS (PAAD) und der Deutschen Gesellschaft für Pädiatrische Infektiologie (DGPI). Monatsschr Kinderheilkd 149: 1372–1382

    Article  Google Scholar 

  3. Dunn D, HIV Paediatric Prognostic Markers Collaborative Study Group (2003) Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 362: 1605–1611

    Article  PubMed  Google Scholar 

  4. The European Collaborative Study (1994) Natural history of vertically acquired human immunodeficiency virus-1 infection. Pediatrics 94: 815–819

    PubMed  Google Scholar 

  5. Berk DR, Falkovitz-Halpern MS, Hill DW (2005) Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. JAMA 293: 2221–2231

    Article  PubMed  Google Scholar 

  6. Nachman SA, Stanley K, Yogev R et al. (2000) Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA 283: 492–498

    Article  PubMed  Google Scholar 

  7. van Rossum AM, Fraaij PL, de Groot R (2002) Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2: 93–102 Review

    Article  PubMed  Google Scholar 

  8. Kline MW (2003) Human immunodeficiency virus protease inhibitors. Pediatr Infect Dis J 22: 1085–1087

    PubMed  Google Scholar 

  9. Khanlou H, Yeh V, Guyer B, Farthing C (2005) Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naïve HIV-infected patients. AIDS Patient Care STDS 19: 135–140

    Article  Google Scholar 

  10. Saez-Llorens X, Nelson RP Jr, Emmanuel P et al. (2001) A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. Pediatrics 107: E4

    Article  PubMed  Google Scholar 

  11. Wells CJ , Sharland M, Smith CJ et al. (2002) Triple nucleoside analogue therapy with zidovudine (AZT), lamivudine (3TC) and abacavir (ABC) in paediatric HIV London South Network (PHILS-NET) cohort. XIV International AIDS Conference. Barcelona, Spain, July 7-12, Abstract TuBeB4625

  12. Moyle GJ (2003) Where now for Trizivir? Role of the triple-NRTI pill post-ACTG 5095. AIDS Read 13: 223–224, 227, 244. Review

    PubMed  Google Scholar 

  13. Feinberg J (2003) Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Trizivir vs. efavirenz: results from ACTG 5095. AIDS Clin Care 15: 78–79

    Google Scholar 

  14. Kline MW, Blanchard S, Fletcher CV et al. (1999) A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team. Pediatrics 103: e47

    Article  PubMed  Google Scholar 

  15. Hughes W, McDowell JA, Shenep J et al. (1999) Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother 43: 609–615

    PubMed  Google Scholar 

  16. Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL, PACTG 356 Investigators (2004) A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 350: 2471–2480

    Article  PubMed  Google Scholar 

  17. Wiznia A, Stanley K, Krogstad P et al. (2000) Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. AIDS Res Hum Retroviruses 16: 1113–1121

    Article  PubMed  Google Scholar 

  18. de Martino M, Tovo PA, Balducci M et al. (2000) Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 284: 190–197

    Article  PubMed  Google Scholar 

  19. Starr SE, Fletcher CV, Spector SA et al. (1999) Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 341: 1874–1881

    Article  PubMed  Google Scholar 

  20. Starr SE, Fletcher CV, Spector SA et al. PACTG 382 Study Team. Pediatric AIDS Clinical Trials Group (2002) Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr Infect Dis J 21: 659–663

    Article  PubMed  Google Scholar 

  21. McKinney RE Jr, Johnson GM, Stanley K et al. (1998) A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr 133: 500–508

    Article  PubMed  Google Scholar 

  22. Englund JA, Baker CJ, Raskino C et al. (1997) Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med 336: 1704–1712

    Article  PubMed  Google Scholar 

  23. Chantry CJ, Byrd RS, Englund JA et al. (2003) Pediatric AIDS Clinical Trials Group Protocol 152 Study Team. Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. Pediatr Infect Dis J 22: 1033–1039

    PubMed  Google Scholar 

  24. Paediatric European Network for Treatment of AIDS (PENTA) (2002) Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 359: 733–740

    Article  PubMed  Google Scholar 

  25. Lemberg DA, Palasanthiran P, Goode M, Ziegler JB (2002) Tolerabilities of antiretrovirals in paediatric HIV infection. Drug Saf 25: 973–991 Review

    Article  PubMed  Google Scholar 

  26. de Martino M, Tovo PA, Balducci M et al. (2000) Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 284: 190–197

    Article  PubMed  Google Scholar 

  27. Funk MB, Linde R, Wintergerst U et al. (1999) Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS 13: 1653–1658

    Article  PubMed  Google Scholar 

  28. Krogstad P, Wiznia A, Luzuriaga K et al. (1999) Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 28: 1109–1118

    PubMed  Google Scholar 

  29. Aboulker JP, Babiker A, Chaix ML et al. (2004) Paediatric European Network for Treatment of AIDS. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 18: 237–245

    PubMed  Google Scholar 

  30. Saez-Llorens X, Violari A, Deetz CO et al. (2003) Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 22: 216–224

    Article  PubMed  Google Scholar 

  31. Cvetkovic RS, Goa KL (2003) Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 63: 769–802 Review

    Article  PubMed  Google Scholar 

  32. Luzuriaga K, Bryson Y, McSherry G et al. (1996) Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 174: 713–721

    PubMed  Google Scholar 

  33. Luzuriaga K, Bryson Y, Krogstad P et al. (1997) Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 336: 1343–1349

    Article  PubMed  Google Scholar 

  34. Verweel G, Sharland M, Lyall H et al. (2003) Nevirapine use in HIV-1-infected children. AIDS 17: 1639–1647

    Article  PubMed  Google Scholar 

  35. Tudor-Williams G et al. (2002) Baby Cocktail! A protease-sparing 4 drug combination for symptomatic infants, XIV International AIDS Conference .Barcelona, Spain, July 7–12, Abstract MoOrB1129

  36. Teglas JP, Quartier P, Treluyer JM et al. (2001) Tolerance of efavirenz in children. AIDS 15: 241–243

    Article  PubMed  Google Scholar 

  37. Engelhorn C, Hoffmann F, Kurowski M et al. (2004) Longterm pharmacokinetics (PK) of Amprenavir (APV) in combination with delavirdine (DLV) in HIV-infected children. AIDS 18: 1473–1475

    Article  PubMed  Google Scholar 

  38. Watson DC, Farley JJ (1999) Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 18: 682–689

    Article  PubMed  Google Scholar 

  39. Reddington C, Cohen J, Baldillo A et al. (2000) Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J 19: 1148–1153

    PubMed  Google Scholar 

  40. Sharland M, Blanche S, Castelli G et al. (2004) PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 5 [Suppl 2]: 61–86

    Article  PubMed  Google Scholar 

  41. Persaud D, Zhou Y, Siliciano JM, Siliciano RF (2003) Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol 77: 1659–1665

    Article  PubMed  Google Scholar 

  42. Melvin AJ, Lewis PF, Mohan KM et al. (2002) Efficacy and toxicity of antiretroviral therapy using 4 or more agents: application of a strategy for antiretroviral management in human immunodeficiency virus-infected children. Arch Pediatr Adolesc Med 156: 568–573

    PubMed  Google Scholar 

  43. Van Rompay KK, Matthews TB, Higgins J et al. (2002) Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol 76: 6083–6092

    Article  PubMed  Google Scholar 

  44. Turner D, Brenner BG, Routy JP et al. (2004) Rationale for maintenance of the M184V resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol 27 [2 Suppl 1]: 31–39

    PubMed  Google Scholar 

  45. Lawrence J, Mayers DL, Hullsiek KH et al. (2003) Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 349: 837–846

    Article  PubMed  Google Scholar 

  46. Church JA, Hughes M, Chen J et al. (2004) Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 23: 713–718

    PubMed  Google Scholar 

  47. Lalezari JP, Henry K, O’Hearn M et al. (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348: 2175–2185

    Article  PubMed  Google Scholar 

  48. Lazzarin A, Clotet B, Cooper D et al. (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348: 2186–2195

    Article  PubMed  Google Scholar 

  49. Croom K, Keam S (2005) Tipranavir: a ritonavir-boosted protease inhibitor. Drugs 65: 1669–1677

    Article  PubMed  Google Scholar 

  50. Cooper D, Hicks C, Cahn P et al. (2005) 24-Week RESIST Study Analyses: the Efficacy of Tipranavir/Ritonavir Is Superior to Lopin.avir/Ritonavir, and the TPV/r Treatment Response is Enhanced by Inclusion of Genotypically Active Antiretrovirals in the Optimized Background Regimen Authors and Affiliations: 12. Conference on Retroviruses and Opportunistic Infections, 22.–25.2.2005 in Boston, USA, Poster 560

  51. Johnson M, DeJesus E, Rodriguez C et al. (2005) The influence of baseline protease inhibitor mutations on the efficacy of Ritonavir-boosted Atazanavir, Atazanavir plus Saquinavir, and Lopinavir/Ritonavir in patients who have experienced virologic failure on multiple HAART regimens. 12. Conference on Retroviruses and Opportunistic Infections, 22.–25.2.2005 in Boston, USA, Abstrakt 711

  52. Kiser J, Rutstein R, Aldrovandi G et al. (2005) Pharmacokinetics of Atazanavir/Ritonavir in HIV-infected Infants, Children, and Adolescents: PACTG 1020A. 12. Conference on Retroviruses and Opportunistic Infections, 22.–25.2.2005 in Boston, USA, Poster 767

  53. Rutstein R, Samson P, Aldrovandi G et al. (2005) Effect of Atazanavir on Serum Cholesterol and Triglyceride Levels in HIV-infected Infants, Children, and Adolescents: PACTG 1020A , and PACTG 1020A Study Team. 12. Conference on Retroviruses and Opportunistic Infections, 22.–25.2.2005 in Boston, USA, Poster 774

  54. Miller V, Sabin C, Hertogs K et al. (2000) Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14: 2857–2867

    Article  PubMed  Google Scholar 

  55. Lawrence J, Mayers DL, Hullsiek KH et al. (2003) Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 349: 837–846

    Article  PubMed  Google Scholar 

  56. Gibb DM, Duong T, Leclezio VA et al. (2004) Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 23: 446–450

    PubMed  Google Scholar 

  57. Williams I AD, Babiker A et al. (2004) A virological benefit from an induction/maintenance strategy: the FORTE trial. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, Poster 564

  58. Mentre F, Duval X, Rey E et al. (2005) Prospective trial to evaluate how therapeutic drug monitoring of protease inhibitors increases virologic success and tolerance of HAART (COPHAR-2 ANRS111 trial). 12. Conference on Retroviruses and Opportunistic Infections, 22.–25.2.2005 in Boston, USA, Poster 639

  59. Haubrich R, Best B, Witt M et al. (2005) Determinants of the need for therapeutic drug monitoring: rates and predictors from CCTG 578. et al. 12. Conference on Retroviruses and Opportunistic Infections, 22.–25.2.2005 in Boston, USA, Poster 640

    Google Scholar 

  60. Gonzalez de Requena D, Bonora S, Canta F et al. (2005) Atazanavir Ctrough is associated with efficacy and safety : definition of therapeutic range. 12. Conference on Retroviruses and Opportunistic Infections, 22.–25.2.2005 in Boston, USA, Poster 645

    Google Scholar 

  61. Burger D, Bergshoeff A, De Groot R et al. (2004) Maintaining the nelfinavir trough concentration above 0.8 mg/l improves virologic response in HIV-1 infected children. J Ped 145: 403–405

    Article  Google Scholar 

  62. Schieferstein C, Buhk T, Management von Nebenwirkungen. http://www.hiv.net/2010/buch/nw.htm

  63. Farley J, Gona P, Crain M et al. (2005) Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4–19 years old) in Pediatric AIDS Clinical Trials Group 219C. J Acquir Immune Defic Syndr 38: 480–487

    Article  PubMed  Google Scholar 

  64. Jaquet D, Levine M, Ortega-Rodriguez E et al. (2000) Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 14: 2123–2128

    Article  PubMed  Google Scholar 

  65. Cheseaux JJ, Jotterand V, Aebi C et al. (2002) Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr 30: 288–293

    PubMed  Google Scholar 

  66. Bergersen BM, Sandvik L, Bruun JN, Tonstad S (2004) Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 23: 625–630

    Article  PubMed  Google Scholar 

  67. Bozette S, Ake C, Tam H et al. (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348: 702–710

    Article  PubMed  Google Scholar 

  68. Sabin C, Morfeldt L, Friis-Moller N et al. (2005) Changes over time in the use of antiretroviral therapy and risk factors for cardiovascular disease in the D:A:D study. 12. Conference on Retroviruses and Opportunistic Infections, 22.–25.2.2005, Boston, USA. Poster 866

  69. McComsey G, Bhumbra N, Ma JF et al. (2003) Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics 111: e275–e281

    Article  PubMed  Google Scholar 

  70. Fisac C, Fumero E, Crespo M et al. (2005) Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 19: 917–925

    Article  PubMed  Google Scholar 

  71. European Paediatric Lipodystrophy Group (2004) Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 18: 1443–1451

    PubMed  Google Scholar 

  72. Carr A, Miller J, Law M, Cooper DA (2000) A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14: F25–F32

    Article  PubMed  Google Scholar 

  73. Chene G, Angelini E, Cotte L et al. (2002) Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 34: 649–657

    Article  PubMed  Google Scholar 

  74. Ribera E, Paradineiro J, Sauleda S et al. (2005) Improvement of subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when Stavudine is switched to tenofovir: the Lipotest study (2005). 12. Conference on Retroviruses and Opportunistic Infections, 22.–25.2.2005 in Boston, USA, Poster 860

  75. Vigano A, Giacomet V, Beretta S et al. (2005) Switching to Stavudine to Tenofovir and Protease Inhibitor to Efavirenz results in a favorable clinical outcome in HIV-infected children. 12. Conference on Retroviruses and Opportunistic Infections, 22.–25.2.2005 in Boston, USA, Poster 770

  76. Church JA, Mitchell WG, Gonzalez-Gomez I et al. (2001) Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. J Pediatr 138: 748–751

    Google Scholar 

  77. Vigano A, Mora S (2004) Adverse effects of antiretroviral therapy: focus on bone density. Expert Opin Drug Saf 3: 199–208

    Article  PubMed  Google Scholar 

  78. Giacomet V, Mora S, Cafarelli L et al. (2005) A 12-Month Treatment with Tenofovir Does Not Result in Bone Mineral Loss in HIV-infected Children. 12. Conference on Retroviruses and Opportunistic Infections, 22.–25.2.2005 in Boston, USA, Abstract 51a

  79. Paterson DL, Swindells S, Mohr J et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133: 21–30

    PubMed  Google Scholar 

  80. Van Dyke RB, Lee S, Johnson GM et al., Pediatric AIDS Clinical Trials Group Adherence Subcommittee Pediatric AIDS Clinical Trials Group 377 Study Team (2002) Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human mmunodeficiency virus infection. Pediatrics 109: e61

    Article  PubMed  Google Scholar 

  81. Giacomet V, Albano F, Starace F et al. (2003) Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study. Acta Paediatr 92: 1398–1402

    Article  PubMed  Google Scholar 

  82. Farley, Hines S, Musk A et al. (2003) Assessment of adherence to antiviral therapy in HIV-infected children using the Medication Event Monitoring System, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. J Acquir Immune Defic Syndr 33: 211–218

    PubMed  Google Scholar 

  83. Sturmer M, Doerr HW, Preiser W (2003) Variety of interpretation systems for human immunodeficiency virus type 1 genotyping: confirmatory information or additional confusion? Curr Drug Targets Infect Disord 3(4): 373–382. Review

    Article  PubMed  Google Scholar 

  84. Durant J, Clevenbergh P, Halfon P et al. (1999) Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353: 2195–2199

    Article  PubMed  Google Scholar 

  85. Cohen CJ, Hunt S, Sension M et al. VIRA3001 Study Team (2002) A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16: 579–588

    Article  PubMed  Google Scholar 

  86. Giaquinto C, Green H, De Rossi et al., Italy. A randomised trial of resistance testing versus no resistance testing in children with virological failure: the PERA (Penta 8) trial, 3rd IAS Conference on HIV pathogenesis and treatment, 24–27 july 2005, Rio de Janeiro, Brazil, Oral abstract session We-Oa-01-06

Download references

Interessenkonflikt

Keine Angaben

Author information

Authors and Affiliations

  1. Universitätskinderklinik Düsseldorf

    Tim Niehues & Jennifer Neubert

  2. Universitätskinderklinik Hannover

    Ulrich Baumann

  3. Universitätskinderklinik Mannheim

    Bernd Buchholz

  4. Universitätskinderklinik Frankfurt

    Dominik Dunsch, Markus Funk & Christoph Königs

  5. Universitätskinderklinik Heidelberg

    Martin Edelhäuser

  6. Kinderklinik und Poliklinik im Dr. von Haunerschen Kinderspital, Klinikum der LMU München, Lindwurmstraße 4, 80337, München

    Gundula Notheis & Uwe Wintergerst

Authors
  1. Tim Niehues
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernd Buchholz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dominik Dunsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Markus Funk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christoph Königs
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Martin Edelhäuser
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jennifer Neubert
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gundula Notheis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Uwe Wintergerst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Uwe Wintergerst.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Niehues, T., Baumann, U., Buchholz, B. et al. Empfehlungen zur antiretroviralen Therapie bei HIV-infizierten Kindern. Monatsschr Kinderheilkd 154, 565–577 (2006). https://doi.org/10.1007/s00112-006-1358-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00112-006-1358-8

Search

Navigation